Diagnosis & Differentiation
Claudin-4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study
Diagnostic Cytopathology 2023 October 13 [Link] Vanlal Hruaii, Balamurugan Thirunavukkarasu, Vindhya Prabha, Sandeep Mathur, Venkateswaran K Iyer, Aruna Nambirajan, Deepali Jain Abstract Background: Claudin-4, a tight junction associated protein expressed in epithelial cells, is purported as a highly specific and sensitive marker for epithelial malignancies. Our aim was to assess the sensitivity, specificity and real-time…
Read MoreGelatinous Pleural Effusion: A Diagnostic Challenge for Pleural Mesothelioma in an 80-Year-Old Man
American Journal of Case Reports 2023 October 4 [Link] Ali M Ibnian, Obaid Ullah Khan, Richard Chan, Umesh Bangalore Lakshminarayana, Fasiha Kiran, Sarah Abed, Rahim Abbas, Ahsan Amir, Noran K Al-Kofahi Abstract BACKGROUND Gelatinous pleural effusion, due to raised hyaluronic acid, can be associated with pleural infection and malignancies, such as tuberculosis, metastatic pleural disease,…
Read MoreUroplakin-IIIb as a novel immunohistochemical marker for mesothelioma
Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…
Read MoreUroplakin-IIIb as a novel immunohistochemical marker for mesothelioma
Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…
Read MoreUroplakin-IIIb as a novel immunohistochemical marker for mesothelioma
Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…
Read MoreNew Immunohistochemical Markers for Pleural Mesothelioma Subtyping
Diagnostics 2023 September 14 [Link] Iosè Di Stefano, Greta Alì, Anello Marcello Poma, Rossella Bruno, Agnese Proietti, Cristina Niccoli, Carmelina Cristina Zirafa, Franca Melfi, Maria Giovanna Mastromarino, Marco Lucchi, Gabriella Fontanini Abstract Pleural mesothelioma (PM) comprises three main subtypes: epithelioid, biphasic and sarcomatoid, which have different impacts on prognosis and treatment definition. However, PM subtyping…
Read MorePleural Fluid-to-Blood BNP Ratio May Contribute to Prognosis in Malignant Pleural Mesothelioma
Clinics and Practice 2023 September 13 [Link] Vasiliki Tsolaki, George E Zakynthinos, Sotirios Zarogiannis, Paris Zygoulis, Ioannis Kalomenidis, Rajesh Jagirdar, Ioannis Triantafyllou, Konstantinos I Gourgoulianis, Demosthenes Makris, Epaminondas Zakynthinos Abstract Background: Brain natriuretic peptide (BNP) seems to be produced from malignant mesothelial cells other than cardiomyocytes. We aimed to evaluate whether an increased pleural fluid-to-blood…
Read MorePleural Fluid-to-Blood BNP Ratio May Contribute to Prognosis in Malignant Pleural Mesothelioma
Clinics and Practice 2023 September 13 [Link] Vasiliki Tsolaki, George E Zakynthinos, Sotirios Zarogiannis, Paris Zygoulis, Ioannis Kalomenidis, Rajesh Jagirdar, Ioannis Triantafyllou, Konstantinos I Gourgoulianis, Demosthenes Makris, Epaminondas Zakynthinos Abstract Background: Brain natriuretic peptide (BNP) seems to be produced from malignant mesothelial cells other than cardiomyocytes. We aimed to evaluate whether an increased pleural fluid-to-blood…
Read MoreMelodic maestros: Unraveling the role of miRNAs in the diagnosis, progression, and drug resistance of malignant pleural mesothelioma
Pathology, Research and Practice 2023 September 13 [Link] Mai A Abd-Elmawla, Sherif S Abdel Mageed, Tohada M Al-Noshokaty, Mohammed S Elballal, Ahmed I Abulsoud, Shereen Saeid Elshaer, Ahmed A El-Husseiny, Doaa Fathi, Heba M Midan, Nehal I Rizk, Mahmoud A Elrebehy, Ghadir A Sayed, Manar Mohammed El Tabaa, Aya Salman, Osama A Mohammed, Alaa Ashraf,…
Read MoreKrebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma
Lung Cancer 2023 September 7 [Link] Paul Stockhammer, Hannah Baumeister, Till Ploenes, Francesco Bonella, Dirk Theegarten, Balazs Dome, Christine Pirker, Walter Berger, Luca Hegedüs, Marcell Baranyi, Martin Schuler, Sophie Deshayes, Servet Bölükbas, Clemens Aigner, Christophe Blanquart, Balazs Hegedüs Abstract Objectives: Pleural mesothelioma (PM) is a rare disease with dismal outcome. Systemic treatment options include chemotherapy…
Read More